Results 201 to 210 of about 248,286 (331)

Impact of noradrenergic inhibition on neuroinflammation and pathophysiology in mouse models of Alzheimer's disease. [PDF]

J Neuroinflammation
Evans AK, Park HH, Woods CE, Lam RK, Rijsketic DR, Xu C, Chu EK, Ciari P, Blumenfeld S, Vidano LM, Saw NL, Heifets BD, Shamloo M.   +12 more
europepmc   +1 more source

Lower density of calretinin‐immunopositive neurons in the putamen of subjects with schizophrenia

Journal of Anatomy, Volume 246, Issue 4, Page 505-516, April 2025.
Recent neuroimaging and histological studies highlight the striatum as a key area involved in SCH, but the specific impairment of neuronal subtypes in subcortical structures is not fully understood. This study is the first detailed investigation of neuroanatomical changes in the putamen in SCH, specifically examining the density of calretinin ...
Paz Kelmer, Paulina Hoppa, Erzsébet Frank, Teadora Tyler, Istvan Adorjan   +4 more
wiley   +1 more source

Comparative Efficacy of Dexmedetomidine and Remifentanil in Reducing Postoperative Pain and Opioid Use: A Systematic Review. [PDF]

Cureus
Al-Hassan A, Weissman B, Chowdhury S, Sawires J, Soti V.   +4 more
europepmc   +1 more source

Intermittent hypoxia increases lipid insulin resistance in healthy humans: A randomized crossover trial

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
This scheme illustrates the main results of the present study showing an increase in circulating free fatty acids (FFA) that are likely to be related to several mechanisms like decrease in FFA insulin sensitivity and increase in FFA production. Significant changes are labelled in white, and non‐significant or hypothesis are labelled in pale green ...
Anne Briançon‐Marjollet, Marie Netchitaïlo, Fanny Fabre, Elise Belaidi, Claire Arnaud, Anne‐Laure Borel, Patrick Levy, Jean‐Louis Pépin, Renaud Tamisier   +8 more
wiley   +1 more source

Monoamine signaling and neuroinflammation: mechanistic connections and implications for neuropsychiatric disorders. [PDF]

Front Immunol
Saggu S, Pless A, Dew E, Ware D, Jiao K, Wang Q.   +5 more
europepmc   +1 more source

A randomised crossover trial of daridorexant for the treatment of chronic insomnia and nocturia

Journal of Sleep Research, EarlyView.
Summary This double‐blind, placebo‐controlled, two‐way crossover trial evaluated the efficacy and safety of daridorexant in patients with chronic insomnia and comorbid nocturia. In total, 60 patients aged ≥55 years with insomnia complaints for ≥3 months, Insomnia Severity Index (ISI) ≥13 and ≥3 voids/night for ≥1 month were randomised (1:1) to ...
Katharina Lederer, Heike Benes, Alan Fine, Sylvia Shoffner, Sandro Bacchelli, David Castro Diaz, Jose Emilio Batista, Racheal Rowles, Tobias Di Marco, Michael Meinel   +9 more
wiley   +1 more source

Exploring the Therapeutic Potential of Mitragynine and Corynoxeine: Kratom-Derived Indole and Oxindole Alkaloids for Pain Management. [PDF]

Pharmaceuticals (Basel)
Alford AS, Moreno HL, Benjamin MM, Dickinson CF, Hamann MT.   +4 more
europepmc   +1 more source

Enteric neuropathy and the vagus nerve: Therapeutic implications

Neurogastroenterology &Motility, EarlyView.
Abstract Enteric neuropathies are characterized by abnormalities of gut innervation, which includes the enteric nervous system, inducing severe gut dysmotility among other dysfunctions. Most of the gastrointestinal tract is innervated by the vagus nerve, the efferent branches of which have close interconnections with the enteric nervous system and ...
Bruno Bonaz
wiley   +1 more source

A Scoping Review of the Oral Treatment Options for the Management of Detrusor Sphincter Dyssynergia. [PDF]

Neurourol Urodyn
Tousignant A, Blais MA, Tu LM, Morin M, Ismail S.   +4 more
europepmc   +1 more source

Endocannabinoid signaling in stress, nausea, and vomiting

Neurogastroenterology &Motility, Volume 37, Issue 3, March 2025.
Abstract Background Classical antiemetics that target the serotonin system may not be effective in treating certain nausea and vomiting conditions like cyclic vomiting syndrome (CVS) and cannabinoid hyperemesis syndrome (CHS). As a result, there is a need for better therapies to manage the symptoms of these disorders, including nausea, vomiting, and ...
Marieka V. DeVuono, Thangam Venkatesan, Cecilia J. Hillard   +2 more
wiley   +1 more source